IBBL Joins Combat Against Antimicrobial Resistance

Luxembourg: European Project IBBL Joins Combat Against Antimicrobial Resistance

04.04.2019Editor: Alexander Stark

The Integrated Bio Bank of Luxembourg (IBBL) joins the consortium of Value-Dx, an Innovative Medicines Initiative (IMI) project aiming to combat antimicrobial resistance (AMR) and improve patient outcomes.

Respiratory tract infections acquired in community care settings are the most frequent cause of medical consultation and inappropriate antibiotic use.
(Source: Pixabay / CC0 )

Dudelange/Luxembourg — Diagnostics are deemed instrumental in guiding healthcare professionals in treating infectious diseases. However, in community care settings antibiotics are often overused and unnecessarily prescribed, accelerating AMR. Value-Dx is a European-wide approach aiming to generate evidence on the medical, economic, and public health value of diagnostics in tackling AMR.

The project will focus on acute respiratory tract infections acquired in community care settings as they are the most frequent cause of medical consultation and inappropriate antibiotic use. The outcomes of Value-Dx could apply to other common infections such as urinary tract infections, blood stream infections, and hospital-acquired respiratory tract infections. The purpose of the porject is to transform medical practice to achieve more personalised, evidence-based antibiotic prescription and use in community care settings through the widespread use of clinical and cost-effective innovative diagnostic strategies.

A new approach developed by scientists at the Friedrich-Alexander-Universitiy Nuremberg-Erlangen could be used as a starting point for the development of new antibiotics. (Pixaby)

The project consortium, coordinated by the University of Antwerp, includes 26 partners from academia, industry and other organisations. Specifically, IBBL will support the creation and maintenance of a biobank of clinical samples, pathogens and DNA isolated from Community-Acquired Acute Respiratory Tract Infections (CA-Arti) patients, as well as the establishment of a database and repository of all data collected within Value-Dx. Moreover, IBBL will lead the development of a business plan for the creation and maintenance of a biobank of clinical specimens, strains and DNA.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:45848345)